Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Cousin, Sophie; Cantarel, Coralie; Guégan, Jean‐Philippe; Gomez‐Roca, Carlos; Metges, Jean‐Philippe; Adenis, Antoine; Pernot, Simon; Bellera, Carine; Kind, Michèle; Auzanneau, Céline; Le Loarer, François; Soubeyran, Isabelle; Bessede, Alban; Italiano, Antoîne

doi:10.1158/1078-0432.ccr-20-3416

Public

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Published in Clinical Cancer Research • Jan 25, 2021

Authors:

Sophie Cousin

Coralie Cantarel

Jean‐Philippe Guégan

Abstract

Abstract Purpose: Regorafenib is synergistic with immune checkpoint inhibition in colorectal cancer preclinical models. Patients and Methods: This was a single-arm, multicentric phase II trial. Regorafenib was given 3 weeks on/1 week off, 160 mg every day; avelumab 10 mg/kg i.v. was given every 2 we...

Subject

Regorafenib

Medicine

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!